{
    "nct_id": "NCT04076579",
    "official_title": "Phase II Multi-Center Trial of Trabectedin in Combination With Olaparib in Advanced Unresectable or Metastatic Sarcoma",
    "inclusion_criteria": "Key Inclusion Criteria\n\n* Age ≥ 16 years\n* Advanced unresectable or metastatic sarcoma\n\n  * Cohort 1: Leiomyosarcoma (LMS)/Liposarcoma (LPS)\n  * Cohort 2: Other sarcoma histologies (excluding gastrointestinal stromal tumors)\n* Received at least 1 prior standard chemotherapy. For cohort 1 patients, this must have included a prior anthracycline.\n* Measurable disease by RECIST 1.1\n* Adequate hematologic, renal, hepatic function\n* Adequate creatine phosphokinase\n* ECOG performance status ≤ 1\n* Left ventricular ejection fraction (LVEF) >= institutional lower limit of normal (LLN)\n* Women of childbearing potential and men must agree to use adequate contraception from signing informed consent to at least 6 months (females) and 5 months (men) after study drug treatment\n\nKey Exclusion Criteria\n\n* Prior therapy with PARP inhibitor, including olaparib\n* Prior therapy with trabectedin\n* Additional active malignancy or treatment for alternative cancer (excluding non-melanoma skin cancer) requiring treatment within the past two years\n* Pregnant or breastfeeding women\n* Known hypersensitivity to trabectedin or olaparib\n* Other exclusions per protocol\nHealthy volunteers allowed\nMust have minimum age of 16 Years",
    "exclusion_criteria": "",
    "miscellaneous_criteria": ""
}